Pemigatinib: NCCN Guidelines

Al B. Benson, MD, FACP, FASCO, professor of medicine and director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center, discusses hepatobiliary cancer research that may affect future NCCN guidelines.

Michael I. D'Angelica, MD, FACS, director of the Hepatopancreatobiliary Fellowship Program at Memorial Sloan Kettering Cancer Center, discusses the NCCN guidelines for hepatobiliary cancers.

The addition of immunotherapy and targeted therapies to the NCCN guidelines in bile duct cancer means that tumor mutation profiling is now called for to guide treatment decisions.

Al B. Benson, MD, FACP, FASCO, professor of medicine and director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center, discusses the potential for neoadjuvant intervention in hepatobiliary cancers.

The EMA panel's nod pemigatinib in bile duct cancer is the latest positive news for the targeted therapy after its FDA approval and appearance in the NCCN Guidelines.